*3.2.7.2 Cervical cancer*

Techniques that combine the ability to identify technetium-99 and a blue dye have been widely used for sentinel lymph node biopsy (SLNB), but there has recently been a surge of interest in the use of fluorescent staining, such as indocyanine green (ICG), to improve the rate of SLN detection. Even though recent guidelines recommend sentinel lymph node biopsy in addition to PLND, SLN biopsy alone is not yet the gold standard because there is insufficient prospective evidence, especially in terms of long-term oncological protection. The prospective randomized clinical trial SENTICOL III will answer to these signaled issues, as a study by Balaya et al. [12] mentions. In addition to the facts mentioned above, the prospectively randomized FILM trial evaluated ICG to be superior in lymph node detection compared to isosulfan blue dye in patients with stage I endometrial or cervical cancer, an evaluation performed by Frumovitz and team [13]. Meanwhile, the study's conclusions created a context for the FDA's approval of ICG for lymph node mapping. NCCN guidelines mention sentinel lymph node mapping by ICG in cervical cancer patients, according to Koh et al. [14].
